Switch theme
Sign up to access all valuation multiples
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
2008
61
LTM Revenue $5.8M
LTM EBITDA -$16.1M
$121M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scancell has a last 12-month revenue of $5.8M and a last 12-month EBITDA of -$16.1M.
In the most recent fiscal year, Scancell achieved revenue of n/a and an EBITDA of -$8.9M.
Scancell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scancell valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $6.6M | n/a | $5.8M | XXX |
| Gross Profit | n/a | $6.0M | n/a | XXX | XXX |
| Gross Margin | NaN% | 90% | NaN% | XXX | XXX |
| EBITDA | -$0.2M | -$15.3M | -$8.9M | -$16.1M | XXX |
| EBITDA Margin | -Infinity% | -231% | -Infinity% | -277% | XXX |
| Net Profit | -$2.6M | -$15.0M | -$7.4M | XXX | XXX |
| Net Margin | -Infinity% | -226% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | $5.2M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Scancell's stock price is GBP 0 (or $0).
Scancell has current market cap of GBP 89.7M (or $113M), and EV of GBP 96.1M (or $121M).
See Scancell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $113M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Scancell has market cap of $113M and EV of $121M.
Scancell's trades at 20.8x LTM EV/Revenue multiple, and -7.5x LTM EBITDA.
Analysts estimate Scancell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Scancell and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $121M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.4x | XXX | XXX | XXX |
| P/E | -9.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpScancell's NTM/LTM revenue growth is -63%
Scancell's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Scancell's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Scancell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Scancell and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scancell acquired XXX companies to date.
Last acquisition by Scancell was XXXXXXXX, XXXXX XXXXX XXXXXX . Scancell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Scancell founded? | Scancell was founded in 2008. |
| Where is Scancell headquartered? | Scancell is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Scancell have? | As of today, Scancell has 61 employees. |
| Who is the CEO of Scancell? | Scancell's CEO is Dr. Philip John L'Huillier. |
| Is Scancell publicy listed? | Yes, Scancell is a public company listed on LON. |
| What is the stock symbol of Scancell? | Scancell trades under SCLP ticker. |
| When did Scancell go public? | Scancell went public in 2010. |
| Who are competitors of Scancell? | Similar companies to Scancell include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scancell? | Scancell's current market cap is $113M |
| What is the current revenue of Scancell? | Scancell's last 12-month revenue is $5.8M. |
| What is the current EBITDA of Scancell? | Scancell's last 12-month EBITDA is -$16.1M. |
| What is the current EV/Revenue multiple of Scancell? | Current revenue multiple of Scancell is 20.8x. |
| What is the current EV/EBITDA multiple of Scancell? | Current EBITDA multiple of Scancell is -7.5x. |
| Is Scancell profitable? | Yes, Scancell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
